Clinical Trial Results:
Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer
Summary
|
|
EudraCT number |
2009-018025-73 |
Trial protocol |
DE |
Global end of trial date |
19 Jul 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2022
|
First version publication date |
04 Jun 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GMIHO-008/2008
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01320111 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,
|
||
Sponsor organisation address |
Almstadtstraße 7, Berlin, Germany, 10119
|
||
Public contact |
CRO, iOMEDICO AG, 0049 761152420, info@iomedico.com
|
||
Scientific contact |
CRO, iOMEDICO AG, 0049 761152420, info@iomedico.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Dec 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
19 Jul 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jul 2014
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
This Study will assess the potential prolongation in progression free survival in patients with metastatic breast cancer in combination with standard chemotherapy paclitaxel compared with the paclitaxel monotherapy.
|
||
Protection of trial subjects |
The conduct of this study was in compliance with the Good Clinical Practice Guidelines and under the guiding principles detailes in the Declaration of Helsinki. The study waas also carried out in keeping with applicable local law(s) and regulation(s).
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
18 Aug 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 60
|
||
Worldwide total number of subjects |
60
|
||
EEA total number of subjects |
60
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
60
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
The trial was initiated in July 2010 and recruitment were stopped in November 2012 for an interim analysis. Based on the results, recruitment was terminated. A total of 60 (Arm A: 30, Arm B: 30) patients were enrolled at 21 sites in Germany. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
The patients were randomised between the study groups and stratified according to line of treatment (2nd or 3rd) and pretreatment with bevacizumab. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall period
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Arm A (Standard treatment) | |||||||||||||||||||||
Arm description |
Paclitaxel monotherapy with 80 mg/m² as one-hour i.v. infusion on day 1, 8, 15 every 28 days (one cycle). Dosing levels for dose reduction: 61.6 mg/m² and 45.6 mg/m². | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Paclitaxel
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
80 mg/m² as one-hour i.v. infusion on day 1, 8, 15 every 28 days (one cycle)
|
|||||||||||||||||||||
Arm title
|
Arm B (Test treatment) | |||||||||||||||||||||
Arm description |
Combination therapy with paclitaxel 80 mg/m2 as one-hour i.v. infusion on day 1, 8, 15 and sorafenib 400 mg orally twice daily (bid), i.e. 2x200 mg tablets in the morning and 2x200 mg tablets in the evening, taken continuously throughout 28-day cycles. Sorafenib levels for dose escalation and dose reductions: 200 mg in the morning, 200 mg in the evening (200 mg bid) and 200 mg in the morning, 400 mg in the evening. Paclitaxel levels for dose reductions: 61.6 mg/m² and 45.6 mg/m². | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Paclitaxel
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
paclitaxel 80 mg/m2 as one-hour i.v. infusion on day 1, 8, 15
|
|||||||||||||||||||||
Investigational medicinal product name |
Sorafenib
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
Nexavar®
|
|||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||
Dosage and administration details |
400 mg orally twice daily (bid) taken continuously throughout 28-day cycles
|
|||||||||||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Arm A (Standard treatment)
|
||
Reporting group description |
Paclitaxel monotherapy with 80 mg/m² as one-hour i.v. infusion on day 1, 8, 15 every 28 days (one cycle). Dosing levels for dose reduction: 61.6 mg/m² and 45.6 mg/m². | ||
Reporting group title |
Arm B (Test treatment)
|
||
Reporting group description |
Combination therapy with paclitaxel 80 mg/m2 as one-hour i.v. infusion on day 1, 8, 15 and sorafenib 400 mg orally twice daily (bid), i.e. 2x200 mg tablets in the morning and 2x200 mg tablets in the evening, taken continuously throughout 28-day cycles. Sorafenib levels for dose escalation and dose reductions: 200 mg in the morning, 200 mg in the evening (200 mg bid) and 200 mg in the morning, 400 mg in the evening. Paclitaxel levels for dose reductions: 61.6 mg/m² and 45.6 mg/m². |
|
|||||||||||||
End point title |
Progression-free survival (PFS) | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
from randomisation to disease progression or death
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary efficacy | ||||||||||||
Comparison groups |
Arm A (Standard treatment) v Arm B (Test treatment)
|
||||||||||||
Number of subjects included in analysis |
50
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0409 | ||||||||||||
Method |
Logrank | ||||||||||||
Confidence interval |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
from randomisation until disease progression or death
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
16.0
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Apart from 1 patient in Arm A, all patients experienced at least 1 adverse event. The most common adverse events of any toxicity grade in Arm A were peripheral neuropathy (55% of patients), fatigue (45%), diarrhoea (41%) and alopecia (41%). In Arm B, the most common adverse events were diarrhoea (57%), fatigue (50%), mucositis oral (39%) and peripheral neuropathy (36%). |
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
01 Dec 2010 |
Study protocol (3.0, 02 Nov 2010): Clarification of wording of inclusion/exclusion criteria; formal corrections/changes; subsequent submission of study sites; |
||||||
05 Apr 2013 |
Study protocol (4.0, 15 Feb 2013): Formal implementation of temporary halt of recruitment after recruitment of the 60. patient (measure not caused by safety issue); implementation of a prospective efficacy interim analysis (including enhancement of required total patient number (128 to 148); prolongation of recruitment phase); formal corrections/changes |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
Premature study termination due to futility (decision based on results of prospective efficacy interim analysis July/2013); recruitment was not resumed; study continued regular follow-up phase as per protocol. |